← Eichor
Condition: Lupus Or Sle Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Lupus Or Sle

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · 18 location(s) · Regeneron Pharmaceuticals · NCT06975787Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Sy
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT05927688A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · 101 location(s) · Novartis Pharmaceuticals · NCT06581198A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I
Phase 2 · 96 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015983A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants Wit
Phase 1 · 37 location(s) · AstraZeneca · NCT06916806A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Phase 3 · 13 location(s) · EMD Serono Research & Development Institute, Inc. · NCT07355218A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Phase 3 · 13 location(s) · EMD Serono Research & Development Institute, Inc. · NCT07332481NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
Phase 1 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06676631UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
Phase 1 · 1 location(s) · Nanjing IASO Biotechnology Co., Ltd. · NCT07109986Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
Phase N/A · 22 location(s) · AstraZeneca · NCT07330245CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06822881A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arth
Phase 1 · 9 location(s) · Eli Lilly and Company · NCT07276958A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
Phase 1/Phase 2 · 7 location(s) · DualityBio Inc. · NCT06625671A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Brea
Phase 1 · 54 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT05869955An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT07174843A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Phase 1 · 18 location(s) · Merck Sharp & Dohme LLC · NCT07363590Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From
Phase 1/Phase 2 · 1 location(s) · Alice Bertaina · NCT05508009Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Phase 4 · 1 location(s) · Tongji Hospital · NCT07077486Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Nanjing Bioheng Biotech Co., Ltd. · NCT06548607A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (R
Phase 1 · 3 location(s) · Capstan Therapeutics · NCT06917742Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06350110SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523542Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07361094A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephrit
Phase 2 · 17 location(s) · Hoffmann-La Roche · NCT07598396Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Phase 1 · 33 location(s) · AstraZeneca · NCT07201558the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT07339540A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the
Phase 2 · 32 location(s) · Ventus Therapeutics U.S., Inc. · NCT07260877IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Phase 2 · 3 location(s) · David Ware Branch · NCT03152058A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Dis
Phase 4 · 4 location(s) · Bristol-Myers Squibb · NCT06875960Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
Phase N/A · 1 location(s) · Stefan Lujinschi · NCT07575347
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.